{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T07:58:42Z","timestamp":1757577522187,"version":"3.37.3"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005151","name":"Tupperware","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005151","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UL1TR002544"],"award-info":[{"award-number":["UL1TR002544"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Anaerobe"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.anaerobe.2024.102894","type":"journal-article","created":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T06:19:04Z","timestamp":1723097944000},"page":"102894","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["The impact of 30-day antecedent antibiotic exposure on Clostridioides difficile ribotype patterns and the relationship with clinical outcomes: A single center study"],"prefix":"10.1016","volume":"89","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1239-3510","authenticated-orcid":false,"given":"Majd","family":"Alsoubani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer K.","family":"Chow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angie Mae","family":"Rodday","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura A.","family":"McDermott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seth T.","family":"Walk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David R.","family":"Snydman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2019","series-title":"Antibiotic Resistance Threats in the United States, 2019","key":"10.1016\/j.anaerobe.2024.102894_bib1"},{"issue":"18","key":"10.1016\/j.anaerobe.2024.102894_bib2","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1056\/NEJMra0707500","article-title":"Clostridium difficile\u2014more difficult than ever","volume":"359","author":"Kelly","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"23","key":"10.1016\/j.anaerobe.2024.102894_bib3","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa051590","article-title":"An epidemic, toxin gene\u2013variant strain of Clostridium difficile","volume":"353","author":"McDonald","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.anaerobe.2024.102894_bib4","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/nrmicro2164","article-title":"Clostridium difficile infection: new developments in epidemiology and pathogenesis","volume":"7","author":"Rupnik","year":"2009","journal-title":"Nat. Rev. Microbiol."},{"issue":"22","key":"10.1016\/j.anaerobe.2024.102894_bib5","first-page":"1645","article-title":"Epidemics of diarrhea caused by a clindamycin-resistant strain of Clostridium difficile in four hospitals","volume":"341","author":"Johnson","year":"1999"},{"issue":"3","key":"10.1016\/j.anaerobe.2024.102894_bib6","first-page":"273","article-title":"A large outbreak of Clostridium difficile\u2013associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use","volume":"26","author":"Muto","year":"2005"},{"issue":"9","key":"10.1016\/j.anaerobe.2024.102894_bib7","first-page":"3180","article-title":"Clostridium difficile infections in a Canadian tertiary care hospital before and during a regional epidemic associated with the BI\/NAP1\/027 strain","volume":"52","author":"Labb\u00e9","year":"2008"},{"issue":"11","key":"10.1016\/j.anaerobe.2024.102894_bib8","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1086\/430315","article-title":"Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada","volume":"40","author":"P\u00e9pin","year":"2005","journal-title":"Clin. Infect. Dis."},{"issue":"12","key":"10.1016\/j.anaerobe.2024.102894_bib9","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1111\/j.1572-0241.2007.01539.x","article-title":"Outcomes of Clostridium difficile-associated disease treated with metronidazole or vancomycin before and after the emergence of NAP1\/027","volume":"102","author":"P\u00e9pin","year":"2007","journal-title":"Official journal of the American College of Gastroenterology ACG"},{"key":"10.1016\/j.anaerobe.2024.102894_bib10","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.anaerobe.2019.102072","article-title":"Increasing antibiotic resistance in Clostridioides difficile: a systematic review and meta-analysis","volume":"58","author":"Saha","year":"2019","journal-title":"Anaerobe"},{"issue":"1","key":"10.1016\/j.anaerobe.2024.102894_bib11","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/cid\/ciae087","article-title":"Reduced vancomycin susceptibility in Clostridioides difficile is associated with lower rates of initial cure and sustained clinical response","volume":"79","author":"Eubank","year":"2024","journal-title":"Clin. Infect. Dis."},{"article-title":"Epidemiologic trends in Clostridium difficile isolate ribotypes in United States from 2010 to 2014","year":"2017","series-title":"Open Forum Infectious Diseases","key":"10.1016\/j.anaerobe.2024.102894_bib12"},{"key":"10.1016\/j.anaerobe.2024.102894_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.anaerobe.2020.102185","article-title":"Epidemiologic trends in Clostridioides difficile isolate ribotypes in United States from 2011 to 2016","volume":"63","author":"Snydman","year":"2020","journal-title":"Anaerobe"},{"issue":"10","key":"10.1016\/j.anaerobe.2024.102894_bib14","doi-asserted-by":"crossref","first-page":"6437","DOI":"10.1128\/AAC.00845-15","article-title":"US-based national sentinel surveillance study for the epidemiology of Clostridium difficile-associated diarrheal isolates and their susceptibility to fidaxomicin","volume":"59","author":"Snydman","year":"2015","journal-title":"Antimicrobial agents chemotherapy"},{"issue":"4","key":"10.1016\/j.anaerobe.2024.102894_bib15","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1128\/JCM.03591-14","article-title":"Evaluation of portability and cost of a fluorescent PCR ribotyping protocol for Clostridium difficile epidemiology","volume":"53","author":"Martinson","year":"2015","journal-title":"J. Clin. Microbiol."},{"issue":"9","key":"10.1016\/j.anaerobe.2024.102894_bib16","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1086\/671728","article-title":"Detection of mixed populations of Clostridium difficile from symptomatic patients using capillary-based polymerase chain reaction ribotyping","volume":"34","author":"Behroozian","year":"2013","journal-title":"Infection control and hospital epidemiology"},{"year":"2015","series-title":"European Committee on Antimicrobial Susceptibility Testing, Breakpoint Tables for Interpretation of MICs and Zone Diameters","author":"Eucast","key":"10.1016\/j.anaerobe.2024.102894_bib17"},{"year":"2023","series-title":"Performance Standards for Antimicrobial Susceptibility Testing. 33rd Ed. CLSI Supplement M100","key":"10.1016\/j.anaerobe.2024.102894_bib18"},{"issue":"5","key":"10.1016\/j.anaerobe.2024.102894_bib19","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J of Chronic Diseases"},{"issue":"1","key":"10.1016\/j.anaerobe.2024.102894_bib20","article-title":"Risk of antibiotics associated with Clostridioides difficile infection: antibiotic stewardship in action","volume":"2","author":"Dysangco","year":"2022","journal-title":"Antimicrobial stewardship & healthcare epidemiology\u202f: ASHE"},{"issue":"8","key":"10.1016\/j.anaerobe.2024.102894_bib21","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofad413","article-title":"Comparison of different antibiotics and the risk for community-associated Clostridioides difficile infection: a case-control study","volume":"10","author":"Miller","year":"2023","journal-title":"Open Forum Infect. Dis."},{"issue":"1","key":"10.1016\/j.anaerobe.2024.102894_bib22","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1161\/CIRCULATIONAHA.106.614859","article-title":"Survival methods","volume":"115","author":"Rao","year":"2007","journal-title":"J Circulation"},{"issue":"10","key":"10.1016\/j.anaerobe.2024.102894_bib23","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.jclinepi.2006.01.014","article-title":"A gentle introduction to imputation of missing values","volume":"59","author":"Donders","year":"2006","journal-title":"J of Clinical Epidemiology"},{"year":"2019","series-title":"Applied Missing Data Analaysis with SPSS and R Studio Amsterdam","author":"Martijn","key":"10.1016\/j.anaerobe.2024.102894_bib24"},{"year":"2001","series-title":"Missing Data","author":"Allison","key":"10.1016\/j.anaerobe.2024.102894_bib25"},{"issue":"1","key":"10.1016\/j.anaerobe.2024.102894_bib26","first-page":"418","article-title":"Fluoroquinolone and macrolide exposure predict Clostridium difficile infection with the highly fluoroquinolone-and macrolide-resistant epidemic C. difficile strain BI\/NAP1\/027","volume":"60","author":"Wieczorkiewicz","year":"2016","journal-title":"J Antimicrobial agentschemotherapy"},{"key":"10.1016\/j.anaerobe.2024.102894_bib27","first-page":"1","article-title":"Antimicrobial resistance in Clostridioides (Clostridium) difficile derived from humans: a systematic review and meta-analysis","volume":"9","author":"Sholeh","year":"2020"},{"issue":"1","key":"10.1016\/j.anaerobe.2024.102894_bib28","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1177\/2049936115622891","article-title":"Recent advances in the understanding of antibiotic resistance in Clostridium difficile infection","volume":"3","author":"Spigaglia","year":"2016","journal-title":"Therapeutic advances in infectious disease"},{"issue":"9","key":"10.1016\/j.anaerobe.2024.102894_bib29","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1086\/592257","article-title":"Emergence of Clostridium difficile infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078","volume":"47","author":"Goorhuis","year":"2008","journal-title":"Clin. Infect. Dis."},{"issue":"4","key":"10.1016\/j.anaerobe.2024.102894_bib30","doi-asserted-by":"crossref","first-page":"243","DOI":"10.3109\/00365548.2011.631029","article-title":"Lack of association of outcomes with treatment duration and microbiologic susceptibility data in Clostridium difficile infections in a non-NAP1\/BI\/027 setting","volume":"44","author":"Venugopal","year":"2012","journal-title":"J Scandinavian journal of infectious diseases"},{"key":"10.1016\/j.anaerobe.2024.102894_bib31","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1186\/1471-2334-10-363","article-title":"Faecal pharmacokinetics of orally administered vancomycin in patients with suspected Clostridium difficile infection","volume":"10","author":"Gonzales","year":"2010","journal-title":"BMC Infect. Dis."},{"issue":"2","key":"10.1016\/j.anaerobe.2024.102894_bib32","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.ijantimicag.2015.03.016","article-title":"Impact of vancomycin faecal concentrations on clinical and microbiological outcomes in Clostridium difficile infection","volume":"46","author":"Thabit","year":"2015","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.anaerobe.2024.102894_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13756-020-00815-5","article-title":"Antimicrobial resistance in Clostridioides (Clostridium) difficile derived from humans: a systematic review and meta-analysis","volume":"9","author":"Sholeh","year":"2020","journal-title":"Antimicrob. Resist. Infect. Control"},{"issue":"7","key":"10.1016\/j.anaerobe.2024.102894_bib34","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1093\/cid\/ciac377","article-title":"Can Clostridium innocuum masquerade as Clostridioides difficile?","volume":"75","author":"Skinner","year":"2022","journal-title":"Clin. Infect. Dis.\u202f: an official publication of the Infectious Diseases Society of America"},{"issue":"1","key":"10.1016\/j.anaerobe.2024.102894_bib35","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1093\/cid\/ciaa912","article-title":"Emergence of clinical Clostridioides difficile isolates with decreased susceptibility to vancomycin","volume":"74","author":"Darkoh","year":"2022","journal-title":"Clin. Infect. Dis.\u202f: an official publication of the Infectious Diseases Society of America"},{"issue":"1","key":"10.1016\/j.anaerobe.2024.102894_bib36","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s13756-020-00765-y","article-title":"The association of a reduced susceptibility to moxifloxacin in causative Clostridium (Clostridioides) difficile strain with the clinical outcome of patients","volume":"9","author":"Krutova","year":"2020","journal-title":"Antimicrob. Resist. Infect. Control"}],"container-title":["Anaerobe"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1075996424000775?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1075996424000775?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T07:11:50Z","timestamp":1726125110000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1075996424000775"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":36,"alternative-id":["S1075996424000775"],"URL":"https:\/\/doi.org\/10.1016\/j.anaerobe.2024.102894","relation":{},"ISSN":["1075-9964"],"issn-type":[{"type":"print","value":"1075-9964"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The impact of 30-day antecedent antibiotic exposure on Clostridioides difficile ribotype patterns and the relationship with clinical outcomes: A single center study","name":"articletitle","label":"Article Title"},{"value":"Anaerobe","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anaerobe.2024.102894","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102894"}}